Potential drug targets and progress towards pharmacologic inhibition of hepatic glucose production.
A number of therapeutic targets are currently under investigation for inhibition of hepatic glucose production with small molecules. Antagonists of the glucagon receptor, glycogen phosphorylase, 11-beta-hydroxysteroid dehydrogenase-1 and fructose 1,6-bisphosphatase are, or have been, under evaluation in human clinical trials. Other strategies, including glucocorticoid receptor antagonists and carnitine palmitoyltransferase inhibitors, are supported by proof of principle studies in man as well as rodents. Several potential targets including glucose-6-phosphatase, glucose-6-phosphatase translocase, glycogen synthase kinase-3, adenosine receptor 2B antagonists, phosphoenolpyruvate carboxykinase and pyruvate dehydrogenase kinase, have been validated by compounds that are effective in animal models. Other targets like PGC-1a and CREB have initial validation support but no medicinal chemistry has been reported.
Kurukulasuriya
R
R
Metabolic Disease Research, Abbott Laboratories, 100 Abbott Park Road, Abbott, Park, IL 60064-6098, USA.
Link
J T
JT
Madar
D J
DJ
Pei
Z
Z
Richards
S J
SJ
Rohde
J J
JJ
Souers
A J
AJ
Szczepankiewicz
B G
BG
D000818:Animals; D003864:Depression, Chemical; D005947:Glucose / Q000096:biosynthesis*; D006801:Humans; D008099:Liver / Q000187:drug effects* / Q000378:metabolism*
D005947:Glucose